company background image
ALPHE logo

Pherecydes Pharma Société anonyme ENXTPA:ALPHE Stock Report

Last Price

€2.00

Market Cap

€14.4m

7D

2.6%

1Y

-53.6%

Updated

26 Jun, 2023

Data

Company Financials +

Pherecydes Pharma Société anonyme

ENXTPA:ALPHE Stock Report

Market Cap: €14.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ALPHE Stock Overview

Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages.

ALPHE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Pherecydes Pharma Société anonyme Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Pherecydes Pharma Société anonyme
Historical stock prices
Current Share Price€2.00
52 Week High€4.36
52 Week Low€1.72
Beta0.99
1 Month Change-0.99%
3 Month Change-18.70%
1 Year Change-53.60%
3 Year Changen/a
5 Year Changen/a
Change since IPO-79.38%

Recent News & Updates

Recent updates

Shareholder Returns

ALPHEFR BiotechsFR Market
7D2.6%1.1%0.2%
1Y-53.6%-3.3%8.6%

Return vs Industry: ALPHE underperformed the French Biotechs industry which returned -25.4% over the past year.

Return vs Market: ALPHE underperformed the French Market which returned 18.9% over the past year.

Price Volatility

Is ALPHE's price volatile compared to industry and market?
ALPHE volatility
ALPHE Average Weekly Movement6.0%
Biotechs Industry Average Movement5.8%
Market Average Movement4.3%
10% most volatile stocks in FR Market9.4%
10% least volatile stocks in FR Market2.2%

Stable Share Price: ALPHE's share price has been volatile over the past 3 months.

Volatility Over Time: ALPHE's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200629Thibaut Fayethttps://www.pherecydes-pharma.com

Pherecydes Pharma Société anonyme develops antibacterial treatments based on the use of bacteriophage viruses or phages. It develops a portfolio of therapeutics, such as anti-staphylococcus aureus for the treatment of bone/joint and diabetic foot ulcer infections; anti-pseudomonas aeruginosa, a phage therapy treatment for respiratory tract infections; and anti-escherichia coli for the treatment of respiratory tract infections. The company was founded in 2006 and is headquartered in Romainville, France.

Pherecydes Pharma Société anonyme Fundamentals Summary

How do Pherecydes Pharma Société anonyme's earnings and revenue compare to its market cap?
ALPHE fundamental statistics
Market cap€14.44m
Earnings (TTM)-€4.85m
Revenue (TTM)€3.16m

4.6x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALPHE income statement (TTM)
Revenue€3.16m
Cost of Revenue€5.42m
Gross Profit-€2.27m
Other Expenses€2.59m
Earnings-€4.85m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

Sep 19, 2023

Earnings per share (EPS)-0.67
Gross Margin-71.91%
Net Profit Margin-153.85%
Debt/Equity Ratio33.7%

How did ALPHE perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.